Alvotech (ALVO) Stock Score, Valuation & Financial Research
Alvotech is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for ALVO
Alvotech currently has a Wall Street Score of 24/100. The stored market price is $5.29. Its financial score is 23/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Alvotech does
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Cu
ALVO financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $5.29
- Market capitalization:
- $1.79B
- Revenue:
- $492.0M
- Net income:
- $-179.6M
- Free cash flow:
- $-114.7M
- Cash:
- $142.8M
- Total debt:
- $1.45B
- EPS:
- -0.58
- Financial score:
- 23/100
- Valuation score:
- 0/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-114.7M, showing cash burn in the current stored period.
- The balance sheet shows $142.8M of cash versus $1.45B of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ALVO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.